THE INDISCRIMINATE USE OF SEMAGLUTIDE (OZEMPIC) FOR WEIGHT LOSS

Authors

DOI:

https://doi.org/10.51891/rease.v11i11.22299

Keywords:

Semaglutide. Ozempic. Obesity. Indiscriminate use. Pharmaceutical care.

Abstract

Introduction: Ozempic (Semaglutide) is a medication used to treat type 2 diabetes. However, it has been used indiscriminately for weight loss, especially by young women. Although it is a proven effective option, its use without medical supervision has harmful consequences for the health of its users due to its adverse effects. Methodology: The methodology used was a literature review, which covers the importance of pharmacists in preventing the indiscriminate use of semaglutide. Electronic databases of scientific articles and journals, such as Scielo, Google Scholar, and the Ministry of Health, among others, were used to conduct this study. The articles were published between 2022 and 2025. Objectives: The general objective of this study is to identify the purpose for which semaglutide was developed and the health harms its indiscriminate use can cause. The specific objectives were: To describe semaglutide; to verify its mechanism of action; List the harmful effects of indiscriminate use of semaglutide; Identify the main benefits of correct use of semaglutide; Understand how pharmacists, through pharmaceutical care, can warn about the indiscriminate use of semaglutide. Conclusion: Although it offers significant benefits in weight loss and improved metabolic parameters, there are risks and challenges, especially when used without medical supervision.

647 359

Downloads

Download data is not yet available.

Author Biographies

  • Jocimar Farias, Universidade Iguaçu

    Graduação em Farmácia. UNIG – Universidade Iguaçu.

  • Rodrigo dos Santos Rodrigues, Universidade Iguaçu

    Graduação em Farmácia. UNIG – Universidade Iguaçu.

  • Leonardo Guimarães de Andrade, Universidade Iguaçu

    Orientador: professor Graduação em Farmácia. UNIG – Universidade Iguaçu.

Published

2025-11-17

How to Cite

Farias, J., Rodrigues, R. dos S., & Andrade, L. G. de. (2025). THE INDISCRIMINATE USE OF SEMAGLUTIDE (OZEMPIC) FOR WEIGHT LOSS. Revista Ibero-Americana de Humanidades, Ciências E Educação, 11(11), 4817-4829. https://doi.org/10.51891/rease.v11i11.22299

Most read articles by the same author(s)

1-10 of 50

Similar Articles

1-10 of 50

You may also start an advanced similarity search for this article.